(S)-2-((S)-3-ISOBUTYL-2,5-DIOXO-4-QUINOLIN-3-YLMETHYL-[1,4]DIAZEPAN-1YL)-N-METHYL-3-NAPHTALEN-2-YL-PROPIONAMIDE

Identification

Name
(S)-2-((S)-3-ISOBUTYL-2,5-DIOXO-4-QUINOLIN-3-YLMETHYL-[1,4]DIAZEPAN-1YL)-N-METHYL-3-NAPHTALEN-2-YL-PROPIONAMIDE
Accession Number
DB04724
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
Not Available
UNII
Not Available
CAS number
Not Available
Weight
Average: 536.6639
Monoisotopic: 536.278741038
Chemical Formula
C33H36N4O3
InChI Key
COVPLULNDBDXTN-KYJUHHDHSA-N
InChI
InChI=1S/C33H36N4O3/c1-22(2)16-30-33(40)36(29(32(39)34-3)19-23-12-13-25-8-4-5-9-26(25)17-23)15-14-31(38)37(30)21-24-18-27-10-6-7-11-28(27)35-20-24/h4-13,17-18,20,22,29-30H,14-16,19,21H2,1-3H3,(H,34,39)/t29-,30-/m0/s1
IUPAC Name
(2S)-N-methyl-2-[(3S)-3-(2-methylpropyl)-2,5-dioxo-4-(quinolin-3-ylmethyl)-1,4-diazepan-1-yl]-3-(naphthalen-2-yl)propanimidic acid
SMILES
[H][[email protected]@](CC1=CC2=CC=CC=C2C=C1)(N1CCC(=O)N(CC2=CC3=CC=CC=C3N=C2)[[email protected]@]([H])(CC(C)C)C1=O)C(O)=NC

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UIntegrin alpha-LNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5326914
PubChem Substance
46505747
ChemSpider
4484198
BindingDB
50161067
ChEMBL
CHEMBL446435
HET
LA1
PDB Entries
1xuo

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00194 mg/mLALOGPS
logP4.35ALOGPS
logP4.67ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.79ChemAxon
pKa (Strongest Basic)6.73ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.1 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity155.69 m3·mol-1ChemAxon
Polarizability59.52 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9201
Blood Brain Barrier-0.6488
Caco-2 permeable-0.5881
P-glycoprotein substrateSubstrate0.9117
P-glycoprotein inhibitor IInhibitor0.9707
P-glycoprotein inhibitor IIInhibitor0.6791
Renal organic cation transporterNon-inhibitor0.6466
CYP450 2C9 substrateNon-substrate0.8282
CYP450 2D6 substrateNon-substrate0.7505
CYP450 3A4 substrateSubstrate0.8099
CYP450 1A2 substrateNon-inhibitor0.6613
CYP450 2C9 inhibitorNon-inhibitor0.5606
CYP450 2D6 inhibitorNon-inhibitor0.8803
CYP450 2C19 inhibitorNon-inhibitor0.5388
CYP450 3A4 inhibitorNon-inhibitor0.5103
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6748
Ames testNon AMES toxic0.6915
CarcinogenicityNon-carcinogens0.9379
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6660 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8971
hERG inhibition (predictor II)Inhibitor0.6501
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinolines and derivatives. These are compounds containing a quinoline moiety, which consists of a benzene ring fused to a pyrimidine ring to form benzo[b]azabenzene.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Not Available
Direct Parent
Quinolines and derivatives
Alternative Parents
Naphthalenes / Alpha amino acids and derivatives / 1,4-diazepanes / Pyridines and derivatives / Fatty amides / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Lactams / Azacyclic compounds
show 4 more
Substituents
Alpha-amino acid or derivatives / Naphthalene / Quinoline / 1,4-diazepane / Diazepane / Fatty amide / Pyridine / Benzenoid / Fatty acyl / Heteroaromatic compound
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinolines, monocarboxylic acid amide, naphthalenes, diazepanone (CHEBI:43574)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated ...
Gene Name
ITGAL
Uniprot ID
P20701
Uniprot Name
Integrin alpha-L
Molecular Weight
128768.495 Da

Drug created on September 11, 2007 11:49 / Updated on December 01, 2017 15:31